




LMA MADgic™

Malleable topical anaesthetic device. Targeted coverage of the nasal/oropharyngeal and hypopharyngeal mucosa. Single use designed to reduce cross contamination.



Malleable topical anaesthetic drug delivery device

LMA MADgic™ is a single-use atomization device. Its unique design has a flexible cannula with memory and a tip that atomizes drugs into a fine mist of particles 30-100 microns in size.¹

Atomization spray

The spray atomizes drugs into a fine mist of particles 30-100 microns in size.³

Pressure

High applied pressure ensures that drugs are atomized into a fine mist of particles through the tip of the device.

Accurate dosing

The syringe enables the accurate measurement of drug to be delivered.

Malleable stylet

360° flexibility of the stylet enables it to be adapted to an individual patient's anatomy,² ensuring the targeted delivery of medication.

Syringe

Available with or without a syringe attached.

“An ideal topical anesthetic should have rapid onset, adequate duration, and minimal or predictable systemic absorption, with the ability to be accurately administered.”

VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel and the National Center for Patient Safety, 2006

Benefits of topical anaesthetic delivered via LMA MADgic™

LMA MADgic™ is a device that has the ability to deliver atomized topical anaesthesia directly to the airway mucosa to suppress airway responses to stimulation and facilitate tracheal intubation.^{2,5,6,7} This may avoid the need to use neuromuscular blockers before intubation.

Topical anaesthetic delivered to the mucosal surface of the larynx may encourage greater haemodynamic stability and reduced airway stimulation in patients:^{6,7}

- ▶ Reduced heartrate vs pre-induction values⁶
- ▶ Reduced cardiovascular response⁷
- ▶ Easier intubation vs saline⁶
- ▶ Fewer attempts for successful insertion of a laryngeal mask⁸

Topical anaesthetic delivered via LMA MADgic™ has been shown to:⁴



Have an onset of action of 2-5 minutes.⁴



Reach peak concentration at 15-20 minutes.⁴



Have a duration of action of 30-60 minutes.⁴



An atraumatic device for the delivery of topical anaesthetic in paediatric patients

The use of LMA MADgic™ to deliver topical anaesthesia to the upper airway increases patient acceptance during difficult awake intubations.¹⁰ Topical anaesthesia can also reduce the risk of laryngospasm vs intravenous drug delivery.^{4,8}

Laryngospasms are three times more likely to occur in a paediatric patient than an adult.⁹

Utilising LMA MADgic™ to apply topical anaesthetic:

- ▶ May reduce coughing or gagging versus intravenous delivery of anaesthetic⁸
- ▶ Replaces the need to deliver anaesthetic via the cricothyroid ligament¹¹

27.6 Incidence of laryngospasm per 1000 paediatric patients⁹

8.6 Incidence of laryngospasm per 1000 adult patients⁹



Consider using LMA MADgic™ to deliver:

Topical anaesthesia for patients requiring:

- ▶ Awake intubation¹⁰
- ▶ Intubation of a difficult airway^{6,10}
- ▶ An anaesthetised airway^{2,6,7,8,12}
- ▶ Insertion of a laryngeal mask airway^{7,8}
- ▶ Nasogastric tube placement

LMA MADgic™: Specifications

	MAD720	MAD700	MAD600
Typical particle size	30-100 microns		
Tip diameter	4.82 mm (0.19 inches)		
Tip length	11.4 cm (4.5 inches)	21.6 cm (8.5 inches)	
System dead space	0.13 ml	0.19 ml	0.25 ml

LMA MADgic™: Product specification

Product code	Quantity/ case	Quantity/ box	Description
MAD720	100	25	Paediatric sized mucosal atomization device for atomizing topical solutions without syringe.
MAD700	100	25	Mucosal atomization device for atomizing topical solutions without syringe.
MAD600	100	25	Mucosal atomization device for atomizing topical solutions with 3 ml syringe.



Find out more about LMA MADgic™



Clinical evidence

For the latest clinical evidence on LMA MADgic™ and LMA Atomization™, visit www.lmaco.com/evidence



For the latest educational videos and clinician testimonials on LMA MADgic™ and LMA Atomization™, visit www.youtube.com/LaryngealMaskAirway



For the latest news from LMA, like us on www.facebook.com/LMAInternational



For product information and access to product instructions for use, visit www.lmaco.com



For information on other products within the Teleflex product portfolio, visit www.teleflex.com



Distributed by:



30-0311 Rev. 02/14

Teleflex **LMA**
www.teleflex.com www.lmaco.com

Copyright © 2014 Teleflex Incorporated. All rights reserved. LMA, LMA Atomization, LMA Better by Design, LMA MADgic, LMA MAD, MAD and MADgic are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. Wolfe-Tory Medical, Inc. is a wholly owned subsidiary of Teleflex Medical.

References:

1. Joshi N., Marjot R. Anaesthesia 2008; **63**: 1255-1267.
2. Xue F.S. et al. BJA 2007; **99** (6): 920-921.
3. Talon M. et al. J Burn Care Res 2009; **30**: 599-605.
4. VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel and the National Center for Patient Safety, 2006.
5. Xue F.S. et al. CJA 2007; **54**: 949-958.
6. Bülow K. et al. Acta Anaesthesiol Scand 1996; **40**: 752-756.
7. Hamaya Y., Dohi S. Anesthesiologist 2000; **93**: 95-103.
8. Cook T.M. et al. Anaesthesia 1996; **51**: 787-790.
9. Olsson G.L., Hallen B. Acta Anaesthesiol Scand 1984; **28**: 567-575.
10. Xue F.S. et al. Chin Med J 2009; **122** (4): 408-415.
11. Difficult airway management at the department of anaesthesiology. URL: <http://faculty.washington.edu/pcolley/>
12. Denlinger J.K. et al. Anesthesiology 1974; **41** (4): 409-412.

For the complete list of LMA MADgic™ references, visit www.lmaco.com/lmamadgic

TELEFLEX HEADQUARTERS INTERNATIONAL, IRELAND
Teleflex Medical Europe Ltd., IDA Business and Technology Park,
Dublin Road, Athlone, Co Westmeath, Ireland
Phone +353 (0)9 06 46 08 00 Fax +353 (0)14 37 07 73
orders.intl@teleflex.com



Manufactured by:
Wolfe Tory Medical, Inc.
79 West 4500 South
Salt Lake City, Utah 84107



Consult IFU on this website:
www.LMACO.com



Printed on paper from
sustainable sources